PRESTIGE CONSUMER HEALTHCARE INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.87 million for the 3-month period ending 2024-12-31, per its 10-Q filed 2025-02-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-02-06
- PRESTIGE CONSUMER HEALTHCARE INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-12-31 was $2.87M, a 16.99% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $2.13M, a 42.14% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $3.42M, a 17.39% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-12-31 was $2.45M, a 0.66% increase year-over-year.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month |
|---|---|---|---|
| 2024-12-31 | $2.87M 10-Q · filed 2025-02-06 | $5.00M derived: sum of 2 quarters · filed 2025-02-06 | $8.42M 10-Q · filed 2025-02-06 |
| 2024-09-30 | $2.13M 10-Q · filed 2024-11-07 | $5.56M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $3.42M 10-Q · filed 2024-08-08 | ||
| 2023-12-31 | $2.45M 10-Q · filed 2025-02-06 | $6.14M derived: sum of 2 quarters · filed 2025-02-06 | $10.28M 10-Q · filed 2025-02-06 |
| 2023-09-30 | $3.69M 10-Q · filed 2024-11-07 | $7.83M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $4.15M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $2.43M 10-Q · filed 2024-02-08 | $5.90M derived: sum of 2 quarters · filed 2024-02-08 | $9.76M 10-Q · filed 2024-02-08 |
| 2022-09-30 | $3.47M 10-Q · filed 2023-11-02 | $7.32M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $3.86M 10-Q · filed 2023-08-03 | ||
| 2021-12-31 | $2.23M 10-Q · filed 2023-02-02 | $5.45M derived: sum of 2 quarters · filed 2023-02-02 | $7.33M 10-Q · filed 2023-02-02 |
| 2021-09-30 | $3.22M 10-Q · filed 2022-11-03 | $5.10M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $1.88M 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | $1.59M 10-Q · filed 2022-02-03 | $4.48M derived: sum of 2 quarters · filed 2022-02-03 | $5.94M 10-Q · filed 2022-02-03 |
| 2020-09-30 | $2.89M 10-Q · filed 2021-11-04 | $4.36M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $1.46M 10-Q · filed 2021-08-05 | ||
| 2019-12-31 | $1.78M 10-Q · filed 2021-02-04 | $4.30M derived: sum of 2 quarters · filed 2021-02-04 | $5.68M 10-Q · filed 2021-02-04 |
| 2019-09-30 | $2.52M 10-Q · filed 2020-11-05 | $3.90M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.38M 10-Q · filed 2020-08-06 | ||
| 2018-12-31 | $1.83M 10-Q · filed 2020-02-06 | $4.50M derived: sum of 2 quarters · filed 2020-02-06 | $6.16M 10-Q · filed 2020-02-06 |
| 2018-09-30 | $2.67M 10-Q · filed 2019-10-31 | $4.33M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $1.66M 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |